In summary, dual EZH2-G9A/GLP inhibition with HKMTI-1-005 shows promise as an approach to promoting the efficacy of ATRA-based therapy in non-APL AML and warrants further investigation. This evidence concerns the gene EZH2 and acute promyelocytic leukemia.